alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 76 studies by Alzheimer's Disease Neuroimaging Initiative · free to read (page 2 of 4) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2022-04-13

Blood pressure variability is an emerging risk factor for cognitive decline and dementia, but mechanisms remain unclear. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2021-06-01

Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. 3 key findings →

Participants: 302 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function

✓ Peer-reviewed alzhub usefulness score 56 out of 100. NeuroImage 2014-10-29

Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer's disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. 4 key findings →

Design: cohort study Participants: 82 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Neurology 2017-10-25

An increased HV:CTV ratio was predictive of faster clinical decline in participants with AD who were clinically indistinguishable at baseline except for a greater dysexecutive presentation. 1 key finding →

Participants: 229 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in computational neuroscience 2019-10-16

As a result, our combined method achieved an area under the receiver operating characteristic (AU-ROC) curve of 98.33, 93.59, 96.83, 94.64, 96.43, and 95.24% for AD vs. MCIs subjects which are high relative to single modality results and other state-of-the-art approaches. 2 key findings →

Participants: 158 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification

✓ Peer-reviewed alzhub usefulness score 55 out of 100. PloS one 2016-02-22

We developed an accurate prognostic model for predicting MCI-to-dementia progression over a three-year period. 4 key findings →

Participants: 139 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Psychiatry research 2011-09-14

Despite numerous studies on the role of medial temporal lobe structures in Alzheimer's disease (AD), the magnitude and clinical significance of amygdala atrophy have been relatively sparsely investigated. 4 key findings →

Participants: 90 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 55 out of 100. NeuroImage. Clinical 2018-07-17

Previous publications indicate that Alzheimer's Disease (AD) related cortical atrophy may develop in asymmetric patterns, with accentuation of the left hemisphere. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurobiology of aging 2020-01-16

The choroid plexus (ChP) is a major source of cerebrospinal fluid (CSF) production, with a direct and indirect role in protein clearance, and pathogenesis of Alzheimer's disease (AD). 3 key findings →

Participants: 509 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-10-09

We replicated the CLU-MS4A4E interaction in a large case-control series and observed APOE ε4 and possible dominant effect. 1 key finding →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 2011-12-21

This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurobiology of aging 2018-10-25

TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) when using clinical criteria to classify Alzheimer's disease (AD). 4 key findings →

Participants: 497 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. NeuroImage 2012-11-07

Hippocampal volumetry derived from structural MRI is increasingly used to delineate regions of interest for functional measurements, assess efficacy in therapeutic trials of Alzheimer's disease (AD) and has been endorsed by the new AD diagnostic guidelines as a radiological marker of disease progression. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Frontiers in neurology 2018-08-14

Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. 4 key findings →

Participants: 124 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Higher rates of decline for women and apolipoprotein E epsilon4 carriers

✓ Peer-reviewed alzhub usefulness score 53 out of 100. AJNR. American journal of neuroradiology 2013-07-04

Age and the apolipoprotein E ε4 allele are well-known risk factors for Alzheimer disease, but whether female sex is also a risk factor remains controversial. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuroimaging predictors of brain amyloidosis in mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of neurology 2013-08-01

As one of the first attempts to use an imaging technique that does not require amyloid-specific radioligands for identification of individuals with brain amyloidosis, our findings could lead to development of multidisciplinary/multimodality brain amyloidosis biomarkers that are reliable, minimally invasive, and widely available. 3 key findings →

Participants: 62 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting MCI outcome with clinically available MRI and CSF biomarkers

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurology 2011-10-12

Incorporating quantitative assessment of learning ability along with vMRI or CSF biomarkers in the clinical workup of MCI can provide critical information on risk of imminent conversion to AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline

✓ Peer-reviewed alzhub usefulness score 52 out of 100. NeuroImage 2007-11-01

Spatial patterns of brain atrophy in mild cognitive impairment (MCI) and Alzheimer's disease (AD) were measured via methods of computational neuroanatomy. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed